肺泰胶囊联合抗结核治疗方案治疗复治肺结核的临床观察

发布时间：2018-01-15 23:03

本文关键词：肺泰胶囊联合抗结核治疗方案治疗复治肺结核的临床观察　出处：《中国中西医结合杂志》2017年10期 　论文类型：期刊论文

【摘要】：目的观察含肺泰胶囊抗结核治疗方案治疗复治肺结核的临床疗效。方法将113例复治肺结核患者按随机数字表法分为治疗组(58例)和对照组(55例)。两组均采用常规抗结核化疗(治疗方案为3H-R-Z-E/6H-R-E),治疗组加服肺泰胶囊2.5 g,每日3次。两组疗程均为9个月。观察两组患者治疗2、5、8个月末的痰菌阴转率,治疗3、6、9个月末的病灶吸收率及空洞闭合率,治疗1个月末的临床症状缓解率和治疗9个月末不良反应的发生情况。结果治疗2、5、8个月末,治疗组痰菌阴转率分别为[75.00%(21/28)、92.86%(26/28)、96.43%(27/28)]明显高于对照组[41.67%(10/24)、70.83%(17/24)、75.00%(18/24),χ~2=5.96、4.92、5.09,P0.05]。治疗3、6、9个月末,治疗组病灶吸收总有效率分别为[81.03%(47/58)、94.83%(55/58)、98.28%(57/58)]高于对照组[43.64%(24/55)、61.82%(34/55)、70.91%(39/55),χ~2=16.91、18.39、16.54,P0.01],且治疗组空洞缩小总有效率分别为[70.00%(28/40)、87.50%(35/40)、95.0%(38/40)]亦优于对照组[27.03%(10/37)、48.65%(18/37)、70.27%(26/37),χ~2=14.20、13.52、8.38,P0.01]。治疗1个月末,治疗组咳嗽、咳痰、咯血、发热、乏力、盗汗、纳差症状的缓解率均高于对照组(χ~2=4.78、5.59、5.40、4.65、4.25、4.79、4.50,P0.05)。治疗组药物不良反应发生率为24.13%(14/58),对照组为29.09%(16/55),两组比较,差异无统计学意义(χ~2=0.36,P0.05)。结论肺泰胶囊与抗结核化疗药物联用治疗复治肺结核,能促进病灶吸收及空洞闭合,加快痰菌转阴。
[Abstract]:Objective To observe the clinical curative effect of Feitai Capsule Containing anti tuberculosis treatment regimen in the treatment of pulmonary tuberculosis. Methods 113 cases of pulmonary tuberculosis were randomly divided into treatment group (58 cases) and control group (55 cases). Two groups were treated with conventional anti tuberculosis chemotherapy (treatment 3H-R-Z-E/ 6H-R-E), the treatment group added Feitai Capsule 2.5 g, 3 times a day. The two groups were treated for 9 months. The sputum of patients in two groups were observed for 2,5,8 at the end of the negative conversion rate of 3,6,9 at the end of the treatment, lesion absorption rate and the cavity closure rate, clinical symptoms for 1 months, the incidence rate of remission and treatment at the end of the 9 month of adverse reaction. The treatment of 2,5,8 at the end of the treatment group, the sputum conversion rate was [75.00% (21/28), 92.86% (26/28), 96.43% (27/28)] was significantly higher than the control group ([41.67% 10/24), 70.83% (17/24), 75% (18/24), 5.96,4.92,5.09 P0.05]. x ~2=, treatment of 3,6,9 the end of the month, the treatment group The total effective rate of lesion absorption were [81.03% (47/58), 94.83% (55/58), 98.28% (57/58)] was higher than the control group [43.64% (24/55), 61.82% (34/55), 70.91% (39/55), X ~2=16.91,18.39,16.54, P0.01], and the treatment group the total efficiency of syringomyelia were [70.00% (28/40), 87.50% (35/40) 95%, (38/40)] is better than that of the control group [27.03% (10/37), 48.65% (18/37), 70.27% (26/37), X ~2=14.20,13.52,8.38, P0.01]. for 1 months, the treatment group cough, expectoration, hemoptysis, fever, fatigue, night sweats, relieve the symptoms of anorexia were higher than that of control group (~2=4.78,5.59,5.40,4.65,4.25,4.79,4.50, P0.05). The incidence of adverse drug reactions in the treatment group was 24.13% (14/58), the control group was 29.09% (16/55), the two groups, the difference was not statistically significant (~2=0.36, P0.05). The treatment of pulmonary tuberculosis combined with pulmonary Thailand capsule and anti tuberculosis drugs, can promote the focus absorption and cavity closure, accelerate phlegm The bacteria turn to the shade.

【作者单位】：浙江省宁波市奉化区人民医院感染科;浙江省宁波市奉化区疾病预防控制中心;
【分类号】：R521
【正文快照】： 肺结核是由结核分枝杆菌引起的严重危害人群健康的慢性呼吸道传染病,数十年来,一直是全球受关注的公共卫生问题之一[1]。我国结核病的发病率在全球排第2位,而肺结核在我国法定报告乙类传染病中发病率和病死率居于首位[2],且流行病学调查显示,近年来其发病率、耐药率和复发率均

【相似文献】